TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29405626
Drug: Atrasentan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 0.75 mg once daily for 6 weeks, followed by random assignment to either placebo or atrasentan 0.75 mg/day for responders (≥30% UACR decrease)
Study: 29405626
Drug: Atrasentan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 0.75 mg/day for non-responders (<30% UACR reduction)
Study: 29406378
Drug: Pediatric residents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric residents as first laryngoscopists in PICUs with a Pediatric Critical Care Medicine fellowship
Study: 29406378
Drug: Pediatric residents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric residents as first laryngoscopists in PICUs without a Pediatric Critical Care Medicine fellowship
Study: 29406378
Drug: ICUs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICUs with a Pediatric Critical Care Medicine fellowship
Study: 29406378
Drug: ICUs without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICUs without a Pediatric Critical Care Medicine fellowship
Study: 29406772
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol combination
Study: 29406772
Drug: Inhaled treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treatments (including vilanterol and fluticasone furoate/vilanterol)
Study: 29406851
Drug: Dobutamine Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine Stress Echocardiography (DSE) with peak stress mean gradient (MG) ≥40 mm Hg
Study: 29406851
Drug: Composite of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite of peak stress MG ≥40 mm Hg and peak stress aortic valve area (AVA) ≤1 cm
Study: 29407124
Drug: Conventional strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional strategy based on treatment of coronary artery disease only with standard of care (n=258)
Study: 29407124
Drug: Conventional strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional strategy based on treatment of coronary artery disease only with standard of care
Study: 29408994
Drug: C-peptide positive
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide positive (C-pos) patients during hypoglycemia (2.5 mmol/L)
Study: 29408994
Drug: C-peptide negative
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-peptide negative (C-neg) patients during hypoglycemia (2.5 mmol/L)
Study: 29409025
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (Nordic diet recommendations and at least 150 minutes of moderate exercise weekly)
Study: 29409462
Drug: Standard treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatments (endoscopy and surgery)
Study: 29409462
Drug: Multimodal treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatments (including chemotherapy, targeted therapies, immunotherapy, radiotherapy, and surgery)
Study: 29410385
Drug: PENFS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PENFS treatment group (10 subjects)
Study: 29410385
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy control group (10 subjects)
Study: 29411338
Drug: Infusion safety
Normalized name: SET,INFUSION SAFETY BRAUN #4252535-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion safety intervention bundle
Study: 29412688
Drug: Long-Acting β-Agonist/Inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-Acting β-Agonist/Inhaled Corticosteroid
Study: 29413684
Drug: HER family
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER family inhibitors (trastuzumab, lapatinib, afatinib)
Study: 29413684
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (lapatinib or afatinib)
Study: 29413684
Drug: Other molecularly
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Other molecularly targeted agents (mTOR, PI3K, NOTCH inhibitors, chemotherapy)
Study: 29414995
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment cohorts
Study: 29415190
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg once daily alone (days 1-4)
Study: 29415190
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg once daily with isoniazid 900 mg, rifapentine 900 mg, and pyridoxine 50 mg (days 5-19)
Study: 29416368
Drug: Nutriage day
Normalized name: NuTriaRX CreamPak KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutriage day cream (morning application)
Study: 29416368
Drug: Nutriage night
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutriage night cream (evening application)
Study: 29416652
Drug: Rituximab 375mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab 375mg/m2 IV infusion 3 times per week for weeks 1-4, along with HD-MTX 3.5g/m2, vincristine, procarbazine, cytarabine, and dexamethasone taper.
Study: 29416986
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m²) in combination with doxorubicin and cyclophosphamide (CAP regimen)
Study: 29417092
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT), 10 hours of treatment
Study: 29417092
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (various sedation methods)
Study: 29419425
Drug: Plerixafor (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (dose escalation)
Study: 29420116
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine (PCV7)
Study: 29420467
Drug: Neratinib (pan-HER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (pan-HER kinase inhibitor)
Study: 29420795
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy in younger patients (<50 years)
Study: 29420795
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy in older patients (50-64 years)
Study: 29420795
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy in younger and older patients
Study: 29421974
Drug: Stanford Leisure-Time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanford Leisure-Time Activity Categorical Item (L-Cat)
Study: 29421974
Drug: L-Cat and
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Cat and adapted GLTEQ measures
Study: 29422881
Drug: Wrist-worn activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrist-worn activity tracking device providing multimodal feedback on daily arm use for 6 weeks
Study: 29424480
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers
Study: 29426386
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy and task-oriented training
Study: 29428177
Drug: Caregiver or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver or adolescent attitudes and beliefs about on-schedule HPV vaccination or HPV vaccine safety
Study: 29428178
Drug: 3-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose regimen of qHPV vaccine
Study: 29428183
Drug: Mass azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mass azithromycin treatment (coverage rate of 84%)
Study: 29428788
Drug: N.I.R. H.E.G.
Approvals — FDA: no, EMA: no, PMDA: no
Description: N.I.R. H.E.G. neurofeedback training
Study: 29429815
Drug: JE-VC (2nd
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-VC (2nd booster dose)
Study: 29429815
Drug: JE-MB (1st
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-MB (1st booster dose)
Study: 29429815
Drug: JE-VC (1st
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-VC (1st booster dose)
Study: 29430250
Drug: Low-intensity extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity extracorporeal shock wave therapy (5 outpatient sessions)
Study: 29430278
Drug: L-AVA group
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-AVA group
Study: 29431735
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment with dichloroacetate (DCA)
Study: 29433560
Drug: Insulin-treated T1DM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-treated T1DM patients
Study: 29433560
Drug: Insulin-treated T2DM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-treated T2DM patients
Study: 29433573
Drug: GH-treated patients
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH-treated patients (GH dose 0.30±0.16 mg/day for females and 0.25±0.10 mg/day for males)
Study: 29435776
Drug: Anagliptin 100
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anagliptin 100 mg orally twice per day
Study: 29435776
Drug: Sitagliptin 50
Normalized name: SITagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 50 mg orally once per day
Study: 29435872
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with weekly paclitaxel (50 mg/m²) and carboplatin, radiation therapy (50.4 Gy/28 Fx or 61.2 Gy/34 Fx)
Study: 29435872
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin
Study: 29437593
Drug: Current immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current immunosuppressive therapies for SR-aGVHD
Study: 29437753
Drug: Multiplex assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiplex assay based on circulating single-molecule amplification and resequencing technology (cSMART)
Study: 29438361
Drug: AZD0424 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0424 (5 mg to 150 mg once-daily or 40 mg bi-daily)
Study: 29438361
Drug: AZD0424 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0424 (doses above 60 mg per day)
Study: 29439003
Drug: Tumour necrosis
Normalized name: Tumour necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour necrosis factor inhibitors (TNFi)
Study: 29439003
Drug: Follow-up at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up at 14-16 weeks after treatment initiation
Study: 29439084
Drug: CYP1A2 activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP1A2 activity measured after administration of caffeine
Study: 29439084
Drug: CYP2B6 activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2B6 activity measured after administration of bupropion
Study: 29439084
Drug: CYP2C9 activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C9 activity measured after administration of tolbutamide
Study: 29439084
Drug: CYP2C19 activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19 activity measured after administration of omeprazole
Study: 29439084
Drug: CYP2D6 activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2D6 activity measured after administration of dextromethorphan
Study: 29439084
Drug: CYP2E1 activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2E1 activity measured after administration of chlorzoxazone
Study: 29439084
Drug: CYP3A4/5 activity
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP3A4/5 activity measured after administration of midazolam
Study: 29439186
Drug: BGB-3111 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGB-3111 and PD-1 antibody
Study: 29439670
Drug: Next-generation DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Next-generation DNA vaccine targeting antigen-presenting cells (APCs) with a sequence encoding a chemokine (MIP-3α)
Study: 29439670
Drug: Next-generation DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Next-generation DNA vaccine
Study: 29439971
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg/day) and Ribavirin (1,000 to 1,200 mg/day) for 3 to 52 weeks
Study: 29440154
Drug: Traditional surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional surgical treatment (full sternotomy)
Study: 29440154
Drug: Transcatheter surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter surgical treatment
Study: 29440404
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) for 4 weeks, intensive daily sessions.
Study: 29443701
Drug: Polypharmacy (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (5 or more unique medications)
Study: 29443701
Drug: No polypharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No polypharmacy (fewer than 5 unique medications)
Study: 29443701
Drug: High-risk medications
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk medications
Study: 29443701
Drug: Prescriptions filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions filled in the 30 preoperative days
Study: 29444231
Drug: MOR208, 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR208, 12 mg/kg intravenously, weekly for 8 weeks, with possible extension based on response.
Study: 29444644
Drug: Cooper balloon
Normalized name: COOPER (AS CUPRIC OXIDE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooper balloon catheter (geometric volume of 2.8 ml)
Study: 29444649
Drug: Therapeutic thoracentesis
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic thoracentesis (withdrawal of pleural fluid in portions of 200 ml up to 1000 ml and 100 ml above 1000 ml)
Study: 29445030
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg orally daily until disease progression, withdrawal from study, or severe toxicity
Study: 29445400
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 × 1 tablets
Study: 29445520
Drug: AZL-M 40-mg
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZL-M 40-mg
Study: 29445520
Drug: AZL-M 80-mg
Normalized name: M
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL-M 80-mg
Study: 29448849
Drug: Small-molecule immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-molecule immune checkpoint inhibitors of PD-1/PD-L1
Study: 29448849
Drug: Antibodies binding
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies binding to PD-1 or PD-L1
Study: 29448936
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) administered by non-rebreather mask for up to 72 hours at 80 ppm
Study: 29449193
Drug: Intrathecal Mesenchymal
Normalized name: Bos taurus mesenchyme preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) treatment
Study: 29450194
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine monitoring and treatment)
Study: 29451701
Drug: Pasireotide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide (600 μg twice daily), Everolimus (10 mg/day), SIRT (SIR-Spheres dose on days 9 and 37)
Study: 29452121
Drug: Tofacitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (5 mg b.i.d. initially, escalated to 10 mg b.i.d. for nonresponders)
Study: 29452209
Drug: Prolactin (PRL)
Normalized name: prolactin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolactin (PRL) treatment in FFA-induced HepG2 cells
Study: 29452209
Drug: Prolactin receptor
Normalized name: Prolactin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolactin receptor (PRLR) overexpression in FFA-induced HepG2 cells
Study: 29452402
Drug: Mitotane monotherapy
Normalized name: Mitotane
DrugBank: Mitotane (DB00648)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitotane monotherapy
Study: 29452421
Drug: LC-MS/MS measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC-MS/MS measurement of cortisol at 30 minutes after intravenous administration of 250 µg tetracosactide acetate.
Study: 29452421
Drug: LC-MS/MS measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC-MS/MS measurement of cortisol at 60 minutes after intravenous administration of 250 µg tetracosactine acetate.
Study: 29452421
Drug: LC-MS/MS measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC-MS/MS measurement of 17-OHP at 30 minutes after intravenous administration of 250 µg tetracosactine acetate.
Study: 29452421
Drug: LC-MS/MS measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC-MS/MS measurement of 17-OHP at 60 minutes after intravenous administration of 250 µg tetracosactine acetate.
Study: 29452808
Drug: Norepinephrine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine administration during early resuscitation
Study: 29453190
Drug: Redesigned monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Redesigned monthly emails with content operationalizing anticipated regret, material incentive (behavior), and problem solving.
Study: 29453305
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose NOACs (1289 patients)
Study: 29453305
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose NOACs (6636 patients)
Study: 29454306
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/d until progression or intolerance
Study: 29454321
Drug: Temsirolimus, 25
Normalized name: Temsirolimus, 25 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus, 25 mg IV weekly until progression, unacceptable toxicities or withdrawal
Study: 29454364
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine A at 2.5 mg/kg/day
Study: 29454660
Drug: CATT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CATT treatment
Study: 29455032
Drug: Sevoflurane administered
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane administered with an expired fraction target of 2% during short-term procedural sedation.
Study: 29456529
Drug: High-dose immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose immunosuppressive therapy combined with autologous CD34+ hematopoietic stem cell transplantation (AHSCT)
Study: 29456629
Drug: Acute vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute vitamin C infusion
Study: 29457758
Drug: Estradiol transdermal
Normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol transdermal patch (0.3 mg/day) during artificial cycle
Study: 29457758
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate suppression and estradiol patches
Study: 29458518
Drug: Daily stress
Normalized name: Natrol Daily Stress Relief Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily stress in girls
Study: 29458699
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 2 weeks nightly
Study: 29459395
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis on the Stroke Emergency Mobile (STEMO)
Study: 29459395
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis through conventional in-hospital care (CC)
Study: 29459395
Drug: Both STEMO
Normalized name: Stemona tuberosa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both STEMO and CC
Study: 29459949
Drug: Nilotinib during
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib during consolidation phase, followed by treatment discontinuation for TFR.
Study: 29459949
Drug: Reinitiated nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reinitiated nilotinib therapy after loss of MMR or confirmed loss of MR4 during TFR.
Study: 29460668
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone in preventing opioid dependence relapse
Study: 29461859
Drug: Five-Grass Pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-Grass Pollen Tablet Sublingual Immunotherapy
Study: 29462123
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg every 2 weeks for ≥2 years or until disease progression or unacceptable toxicity